Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in ...

Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing. | Scribe Therapeutics has put its IPO plans down on ...

A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on ...

For emerging biotech companies, the race to IND is no longer defined by speed alone. | Lonza explains why early de-risking ...

As biomanufacturing investment accelerates, workforce readiness has emerged as a critical bottleneck. | Ohio’s $30M training ...

Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. | Another biotech is squeezing ...

KIT-targeting antibody biotech Jasper Therapeutics is being renewed via a merger with Nasdaq-listed Kira Pharmaceuticals—but ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Abbott turned in a stronger-than-expected second quarter, allaying market concerns that subsidy cuts to the Affordable Care Act by the Trump administration would hurt medtech firms. That worry was ...

GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...

Dimerix has bought an acute kidney injury (AKI) drug from Mission Therapeutics, paying (PDF) $5 million upfront and ...

Takeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to ...